Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 3Recruiting 2Active not recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 2Head & Neck 2Endocrine 2Dermatologic 2CNS 2Thoracic 1Sarcoma 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Genitourinary 1Gastrointestinal 1

Conditions

Thyroid Neoplasms 2Thyroid Carcinoma, Anaplastic 1Thyroid Cancer, Papillary 1

Interventions

pembrolizumab 66Cisplatin 55Radiotherapy, Intensity-Modulated 28Carboplatin 27Nivolumab 26Paclitaxel 21Magnetic Resonance Spectroscopy 21Radiotherapy 20Cetuximab 16Specimen Handling 15Docetaxel 15Radiation 14Gemcitabine 13Fluorouracil 12Biopsy 12durvalumab 11Platinum 11Taxes 10Surveys and Questionnaires 10Drug Therapy 101,2-diaminocyclohexaneplatinum II citrate 10Capecitabine 9trametinib 8tislelizumab 6lenvatinib 6dabrafenib 6cemiplimab 6atezolizumab 6Radiosurgery 6Ipilimumab 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Vemurafenib × Head & Neck × Clear all
NCT01709292 2026-04-16

Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
24 enrolled
EndocrineHead & Neck

Thyroid Cancer, Papillary, Thyroid Neoplasms

NCT03181100 2026-01-09

Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
50 enrolled
EndocrineHead & Neck

Thyroid Neoplasms, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡